Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-23
2006-05-23
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S252100, C514S255050, C514S730000, C544S336000, C544S382000, C544S409000, C544S398000
Reexamination Certificate
active
07049306
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 2002/0052374 (2002-05-01), Rabelink et al.
patent: 2241149 (1997-07-01), None
patent: 2259224 (1998-01-01), None
patent: 19536891 (1997-04-01), None
patent: 2655636 (1997-06-01), None
patent: 19548709 (1997-07-01), None
patent: 19654483 (1998-01-01), None
patent: 19713000 (1998-10-01), None
patent: 116494 (1984-08-01), None
patent: 0 147 211 (1985-07-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0330506 (1989-08-01), None
patent: 0330506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/32383 (1997-04-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/33783 (1998-08-01), None
patent: 9853814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
U.S. Appl. No. 09/910,685, filed Jul. 20, 2001; U.S. Appl. No. 09/910,466, filed Jul. 19, 2001; U.S. Appl. No. 10/218,445, filed on Aug. 15, 2002.
Chem. Abstract114:101454-1991:101454, also cited as Ohta et al, Heterocycles, 31/9,1655-62(1990).
Chem. Abstract 113:130558-1990:530558, also cited as Simchowitz et al, J. Biol. Chem. 265/23,13457-63,(1990).
Chem. Abstract 93:46584-1980:446584, also cited as Ohta et al, Chem. & Pharmaceutical Bulletin,27/12,2980-7,(1979).
Chem.Abstract 69:67676, also cited as Jaeger et al, Chem. Berichte, 101/8,2762-70 (1968).
Chem.Abstract 105:97885, also cited as Colloid & Polumer Sc. 263/10,791-8(1985).
Chem.Abstract 130:52724, also cited as Durette et al in WO 9853814 dated Dec. 1998).
Chem. Abstract 102:24642, also cited as Biziere et al, in EP 116494 dated Aug. 1984.
Abraham, W. M., et al., “α4-Integrins Mediate Antigen -induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93: 776-787 (1994).
Advani, S.B., et al. “Potential Antineoplastic Agents: N-(2-Benzoxazolyl)amino Acid Esters.”J. of Pharm. Sci. 57(10): 1693-1696 (1968).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med. 177: 57-68 (1993).
Baron, J.L., et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Cybulsky, M.I., et al. “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis.”Science. 251: 788-791 (1991).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronecting in Rheumatoid Arthritis Microvasculature.”J. Clin. Invest. 93: 405-416 (1994).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the CLA-4/Fibronectin Binding Site.”Cell. 60: 577-584 (1990).
Gordeev, M.F. “Combinatorial Approaches to pharmacophoric Heterocycles: A Solid-Phase Synthesis of 3,1-Benzoxazine-4-ones.”Biotech. and Bioengineering. 61(1): 13-16 (1998).
Hamann, A., et al. “Role of α4-Integrins in Lymphocute Homing to Mucosal Tissues in Vivo.”J. Immunology. 152: 3283-3292 (1994).
Henke, B.R., et al. “N-(2-Benzoylphenyl)-L-tyrosine :Aryl Agonists. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents.”J. Med. Chem. 41(25): 5020-5036 (1998).
Hladon, B., et al. In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines.Arch. Immunol. Ther. Exp. 40(2): 145-150 (1992). (Abstract).
Hoffman, S., et al. “N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids.”Z. Chem. 12(1): 21-22 (1972), CODEN: ZECEAL (Abstract).
Kawaguchi, S., et al. “VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface.”Japanese J. Cancer Res. 83: 1304-1316 (1992).
Lauri, D., et al. “Decreased adhesion to endothelial cells and matrix proteins of H-2Kbgene transfected tumour cells.”British J. Cancer. 68: 862-867 (1993).
Lazer, E.S., et al., “Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action.”J. Med. Chem. 37(7): 913-923 (1994).
Li, H., et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leeukocyte Adhesion Molecule, in Rabbit Aortic Endothelium.”Arterioscler. Thromb. 13(2): 197-204 (1993).
Ma, D., et al. “Accelerating Effect Induced by the Structure of a-Amino Acid in the Copper Catalyzed Coupling Reaction of Aryl Halides with a-Amino Acids. Synthesis of Benzolactam-V8.”J. Am. Chem. Soc. 120(48): 12459-12467 (1998).
Mulligan, M.S., et al. “Role of β1, β2 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes.”J. Immunol. 150(6): 2407-2417 (1993).
Okarhara, H., et al. “Involvement of Very Late Activation Antigen 4 (V
Dressen Darren B.
Grant Francine S.
Konradi Andrei W.
Pleiss Michael A.
Semko Christopher
Elan Pharmaceuticals Inc.
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Heteroaryl, heterocyclic and aryl compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl, heterocyclic and aryl compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl, heterocyclic and aryl compounds which inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602829